Digestive Diseases and Sciences

, Volume 52, Issue 4, pp 1050–1059 | Cite as

Cellular Localization, Binding Sites, and Pharmacologic Effects of TFF3 in Experimental Colitis in Mice

  • Stine Kjellev
  • Lars Thim
  • Charles Pyke
  • Steen S. Poulsen
Original Paper


Trefoil factors (TFFs) are essential for protection and restitution of the gastrointestinal mucosa but many aspects of TFF biology are unclear. Our aim was to compare the localization of endogenous TFFs and binding sites for injected TFF3 in the colon of healthy and colitic mice and to study the effect of TFF3 on dextrane sulfate sodium (DSS)-induced colitis in mice. Expression of endogenous TFF1-3 was examined by in situ hybridization and immunohistochemistry, and the distribution of intravenously, intraperitoneally, and subcutaneously administered 125I-TFF3 by autoradiography and gamma-counting. The effect of systemically administered TFF3 on DSS-induced colitis was assessed. We found increased expression of endogenous TFF3 and increased binding of injected 125I-TFF3 in the colon of animals with DSS-induced colitis. The distribution of intraperitoneally and subcutaneously administered 125I-TFF3 was comparable. Systemic administration of the peptides reduced the severity of colitis. Expression of endogenous TFF3 and binding of systemically administered TFF3 are increased in DSS-induced colitis. Systemic administration of TFF3 attenuates the disease. These findings suggest a role of TFF3 in mucosal protection.


Animal models Autoradiography Dextran sulfate sodium Experimental colitis Inflammatory bowel disease Intestinal trefoil factor TFF3 



S. Kjellev was supported by a student fellowship from the Danish Ministry for Science, Technology and Innovation. The authors are grateful to the Danish Ministry of Science, Technology and Development and the Danish Research Council for financial support of this study. We thank Grazyna Poulsen, Jette Schousboe, Axel K. Hansen, Bjørg Harryson, Jette Mandelbaum, Steen Kryger, Ann-Christin Løff, and Bodil E. Andersen.


  1. 1.
    Hoffmann W, Jagla W, Wiede A (2001) Molecular medicine of TFF-peptides: from gut to brain. Histol Histopathol 16:319–334PubMedGoogle Scholar
  2. 2.
    Wright NA, Poulsom R, Stamp G, et al. (1992) Trefoil peptide gene expression in gastrointestinal epithelial cells in inflammatory bowel disease. Scand J Gastroenterol Suppl 193:76–82PubMedGoogle Scholar
  3. 3.
    Alison MR, Chinery R, Poulsom R, Ashwood P, Longcroft JM, Wright NA (1995) Experimental ulceration leads to sequential expression of spasmolytic polypeptide, intestinal trefoil factor, epidermal growth factor and transforming growth factor alpha mRNAs in rat stomach. J Pathol 175:405–414PubMedCrossRefGoogle Scholar
  4. 4.
    Xian CJ, Howarth GS, Mardell CE, Cool JC, Familari M, Read LC, Giraud AS (1999) Temporal changes in TFF3 expression and jejunal morphology during methotrexate-induced damage and repair. Am J Physiol 277:G785–G795PubMedGoogle Scholar
  5. 5.
    Mashimo H, Wu DC, Podolsky DK, Fishman MC (1996) Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 274:262–265PubMedCrossRefGoogle Scholar
  6. 6.
    Playford RJ, Marchbank T, Goodlad RA, Chinery RA, Poulsom R, Hanby AM (1996) Transgenic mice that overexpress the human trefoil peptide pS2 have an increased resistance to intestinal damage. Proc Natl Acad Sci USA 93:2137–2142PubMedCrossRefGoogle Scholar
  7. 7.
    Marchbank T, Cox HM, Goodlad RA, Giraud AS, Moss SF, Poulsom R, Wright NA, Jankowski J, Playford RJ (2001) Effect of ectopic expression of rat trefoil factor family 3 (intestinal trefoil factor) in the jejunum of transgenic mice. J Biol Chem 276:24088–24096PubMedCrossRefGoogle Scholar
  8. 8.
    Farrell JJ, Taupin D, Koh TJ, Chen D, Zhao CM, Podolsky DK, Wang TC (2002) TFF2/SP-deficient mice show decreased gastric proliferation, increased acid secretion, and increased susceptibility to NSAID injury. J Clin Invest 109:193–204PubMedCrossRefGoogle Scholar
  9. 9.
    Babyatsky MW, deBeaumont M, Thim L, Podolsky DK (1996) Oral trefoil peptides protect against ethanol- and indomethacin-induced gastric injury in rats. Gastroenterology 110:489–497PubMedCrossRefGoogle Scholar
  10. 10.
    Playford RJ, Marchbank T, Chinery R, Evison R, Pignatelli M, Boulton RA, Thim L, Hanby AM (1995) Human spasmolytic polypeptide is a cytoprotective agent that stimulates cell migration. Gastroenterology 108:108–116PubMedCrossRefGoogle Scholar
  11. 11.
    Poulsen SS, Thulesen J, Christensen L, Nexo E, Thim L (1999) Metabolism of oral trefoil factor 2 (TFF2) and the effect of oral and parenteral TFF2 on gastric and duodenal ulcer healing in the rat. Gut 45:516–522PubMedCrossRefGoogle Scholar
  12. 12.
    Poulsen SS, Kissow H, Hare K, Hartmann B, Thim L (2005) Luminal and parenteral TFF2 and TFF3 dimer and monomer in two models of experimental colitis in the rat. Regul Pept 126:163–171PubMedCrossRefGoogle Scholar
  13. 13.
    FitzGerald AJ, Pu M, Marchbank T, Westley BR, May FE, Boyle J, Yadollahi-Farsani M, Ghosh S, Playford RJ (2004) Synergistic effects of systemic trefoil factor family 1 (TFF1) peptide and epidermal growth factor in a rat model of colitis. Peptides 25:793–801PubMedCrossRefGoogle Scholar
  14. 14.
    Taupin D, Podolsky DK (2003) Trefoil factors: initiators of mucosal healing. Nat Rev Mol Cell Biol 4:721–732PubMedCrossRefGoogle Scholar
  15. 15.
    Cook GA, Familari M, Thim L, Giraud AS (1999) The trefoil peptides TFF2 and TFF3 are expressed in rat lymphoid tissues and participate in the immune response. FEBS Lett 456:155–159PubMedCrossRefGoogle Scholar
  16. 16.
    Tebbutt NC, Giraud AS, Inglese M, Jenkins B, Waring P, Clay FJ, Malki S, Alderman BM, Grail D, Hollande F, Heath JK, Ernst M (2002) Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 8:1089–1097PubMedCrossRefGoogle Scholar
  17. 17.
    Baus-Loncar M, Schmid J, Lalani EN, Rosewel I, Goodlad RA, Stamp GWH, Blin N, Kayademir T (2005) Trefoil factor 2 (Tff2) deficiency in murine digestive tract influences the immune system. Cell Physiol Biochem 16:31–42PubMedCrossRefGoogle Scholar
  18. 18.
    Poulsen SS, Thulesen J, Hartmann B, Kissow HL, Nexo E, Thim L (2003) Injected TFF1 and TFF3 bind to TFF2-immunoreactive cells in the gastrointestinal tract in rats. Regul Pept 115:91–99PubMedCrossRefGoogle Scholar
  19. 19.
    Chinery R, Cox HM (1995) Immunoprecipitation and characterization of a binding protein specific for the peptide, intestinal trefoil factor. Peptides 16:749–755PubMedCrossRefGoogle Scholar
  20. 20.
    Tan XD, Liu QP, Hsueh W, Chen YH, Chang H, Gonzalez-Crussi F (1999) Intestinal trefoil factor binds to intestinal epithelial cells and induces nitric oxide production: priming and enhancing effects of mucin. Biochem J 338(Pt 3):745–751PubMedCrossRefGoogle Scholar
  21. 21.
    Thim L, Mortz E (2000) Isolation and characterization of putative trefoil peptide receptors. Regul Pept 90:61–68PubMedCrossRefGoogle Scholar
  22. 22.
    Otto W, Thim L (2005) Trefoil factor family-interacting proteins. Cell Mol Life Sci 62:2939–2946PubMedCrossRefGoogle Scholar
  23. 23.
    Zhang BH, Yu HG, Sheng ZX, Luo HS, Yu JP (2003) The therapeutic effect of recombinant human trefoil factor 3 on hypoxia-induced necrotizing enterocolitis in immature rat. Regul Pept 116:53–60PubMedCrossRefGoogle Scholar
  24. 24.
    Soriano-Izquierdo A, Gironella M, Massaguer A, May FEB, Salas A, Sans M, Poulsom R, Thim L, Pique JM, Panes JN (2004) Trefoil peptide TFF2 treatment reduces VCAM-1 expression and leukocyte recruitment in experimental intestinal inflammation. J Leukoc Biol 75:214–223PubMedCrossRefGoogle Scholar
  25. 25.
    Thim L, Woldike HF, Nielsen PF, Christensen M, Lynch-Devaney K, Podolsky DK (1995) Characterization of human and rat intestinal trefoil factor produced in yeast. Biochemistry 34:4757– 4764PubMedCrossRefGoogle Scholar
  26. 26.
    Tomita M, Itoh H, Ishikawa N, Higa A, Ide H, Murakumo Y, Maruyama H, Koga Y, Nawa Y (1995) Molecular cloning of mouse intestinal trefoil factor and its expression during goblet cell changes. Biochem J 311(Pt 1):293–297PubMedGoogle Scholar
  27. 27.
    Mashimo H, Podolsky DK, Fishman MC (1995) Structure and expression of murine intestinal trefoil factor: high evolutionary conservation and postnatal expression. Biochem Biophys Res Commun 210:31–37PubMedCrossRefGoogle Scholar
  28. 28.
    Pyke C, Romer J, Kallunki P, Lund LR, Ralfkiaer E, Dano K, Tryggvason K (1994) The gamma 2 chain of kalinin/laminin 5 is preferentially expressed in invading malignant cells in human cancers. Am J Pathol 145:782–791PubMedGoogle Scholar
  29. 29.
    Vestergaard EM, Poulsen SS, Gronbaek H, Larsen R, Nielsen AM, Ejskjaer K, Clausen JT, Thim L, Nexo E (2002) Development and evaluation of an ELISA for human trefoil factor 3. Clin Chem 48:1689–1695PubMedGoogle Scholar
  30. 30.
    Murthy S, Murthy NS, Coppola D, Wood DL (1997) The efficacy of BAY y 1015 in dextran sulfate model of mouse colitis. Inflamm Res 46:224–233PubMedCrossRefGoogle Scholar
  31. 31.
    Bradley PP, Christensen RD, Rothstein G (1982) Cellular and extracellular myeloperoxidase in pyogenic inflammation. Blood 60:618–622PubMedGoogle Scholar
  32. 32.
    Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254PubMedCrossRefGoogle Scholar
  33. 33.
    Williams KL, Fuller CR, Dieleman LA, DaCosta CM, Haldeman KM, Sartor RB, Lund PK (2001) Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology 120:925–937PubMedCrossRefGoogle Scholar
  34. 34.
    Byrne FR, Farrell CL, Aranda R, Rex KL, Scully S, Brown HL, Flores SA, Gu LH, Danilenko DM, Lacey DL, Ziegler TR, Senaldi G (2002) RHuKGF ameliorates symptoms in DSS and CD4(+)CD45RB(Hi) T cell transfer mouse models of inflammatory bowel disease. Am J Physiol Gastrointest Liver Physiol 282:G690–G701PubMedGoogle Scholar
  35. 35.
    Renes IB, Verburg M, Van Nispen DJPM, Taminiau JaJM, Buller HA, Dekker J, Einerhand AWC (2002) Epithelial proliferation, cell death, and gene expression in experimental colitis: alterations in carbonic anhydrase I, mucin MUC2, and trefoil factor 3 expression. Int J Colorect Dis 17:317–326CrossRefGoogle Scholar
  36. 36.
    Wright NA, Poulsom R, Stamp GW, Hall PA, Jeffery RE, Longcroft JM, Rio MC, Tomasetto C, Chambon P (1990) Epidermal growth factor (EGF/URO) induces expression of regulatory peptides in damaged human gastrointestinal tissues. J Pathol 162:279–284PubMedCrossRefGoogle Scholar
  37. 37.
    Poulsom R, Chinery R, Sarraf C, Lalani EN, Stamp G, Elia G, Wright N (1992) Trefoil peptide expression in intestinal adaptation and renewal. Scand J Gastroenterol Suppl 192:17–28PubMedGoogle Scholar
  38. 38.
    Vieten D, Corfield A, Carroll D, Ramani P, Spicer R (2005) Impaired mucosal regeneration in neonatal necrotising enterocolitis. Pediatr Surg Int 21:153–160PubMedCrossRefGoogle Scholar
  39. 39.
    Poulsen SS, Thulesen J, Nexo E, Thim L (1998) Distribution and metabolism of intravenously administered trefoil factor 2/porcine spasmolytic polypeptide in the rat. Gut 43:240–247PubMedCrossRefGoogle Scholar
  40. 40.
    Efstathiou JA, Noda M, Rowan A, Dixon C, Chinery R, Jawhari A, Hattori T, Wright NA, Bodmer WF, Pignatelli M (1998) Intestinal trefoil factor controls the expression of the adenomatous polyposis coli-catenin and the E-cadherin-catenin complexes in human colon carcinoma cells. Proc Natl Acad Sci USA 95:3122–3127PubMedCrossRefGoogle Scholar
  41. 41.
    Kanai M, Mullen C, Podolsky DK (1998) Intestinal trefoil factor induces inactivation of extracellular signal-regulated protein kinase in intestinal epithelial cells. Proc Natl Acad Sci USA 95:178–182PubMedCrossRefGoogle Scholar
  42. 42.
    Emami S, Le Floch N, Bruyneel E, Thim L, May F, Westley B, Rio M, Mareel M, Gespach C (2001) Induction of scattering and cellular invasion by trefoil peptides in src- and RhoA-transformed kidney and colonic epithelial cells. FASEB J 15:351–361PubMedCrossRefGoogle Scholar
  43. 43.
    Rodrigues S, Van Aken E, Van Bocxlaer S, Attoub S, Nguyen QD, Bruyneel E, Westley BR, May FE, Thim L, Mareel M, Gespach C, Emami S (2003) Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling. FASEB J 17:7–16PubMedCrossRefGoogle Scholar
  44. 44.
    Andoh A, Kinoshita K, Rosenberg I, Podolsky DK (2001) Intestinal trefoil factor induces decay-accelerating factor expression and enhances the protective activities against complement activation in intestinal epithelial cells. J Immunol 167:3887–3893PubMedGoogle Scholar
  45. 45.
    Tanaka S, Podolsky DK, Engel E, Guth PH, Kaunitz JD (1997) Human spasmolytic polypeptide decreases proton permeation through gastric mucus in vivo and in vitro. Am J Physiol 272:G1473–G1480PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2007

Authors and Affiliations

  • Stine Kjellev
    • 1
  • Lars Thim
    • 2
  • Charles Pyke
    • 1
  • Steen S. Poulsen
    • 3
  1. 1.Pharmacology Research 4MaaloevDenmark
  2. 2.Protein EngineeringBagsvaerdDenmark
  3. 3.Department of Medical AnatomyThe Panum Institute, University of CopenhagenCopenhagenDenmark

Personalised recommendations